{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:08:38Z","timestamp":1789164518873,"version":"build-2803163510"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0226320","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T18:32:13Z","timestamp":1576607533000},"page":"e0226320","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I\/IIa trial"],"prefix":"10.1371","volume":"14","author":[{"given":"Janin","family":"Chandra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai-Ping","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie L.","family":"Dutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Kinrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Druce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Finlayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry J.","family":"Laing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Koelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8002-4680","authenticated-orcid":true,"given":"Ian H.","family":"Frazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"issue":"9","key":"pone.0226320.ref001","doi-asserted-by":"crossref","first-page":"438","DOI":"10.15698\/mic2016.09.528","article-title":"Genital Herpes: Insights into Sexually Transmitted Infectious Disease","volume":"3","author":"D Jaishankar","year":"2016","journal-title":"Microb Cell"},{"key":"pone.0226320.ref002","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/1471-2334-13-502","article-title":"Herpes simplex virus type 2 and HIV disease progression: a systematic review of observational studies","volume":"13","author":"DH Tan","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"1","key":"pone.0226320.ref003","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.aids.0000198081.09337.a7","article-title":"Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies","volume":"20","author":"EE Freeman","year":"2006","journal-title":"AIDS"},{"issue":"26","key":"pone.0226320.ref004","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1016\/j.vaccine.2015.12.076","article-title":"Status of vaccine research and development of vaccines for herpes simplex virus","volume":"34","author":"C Johnston","year":"2016","journal-title":"Vaccine"},{"issue":"1","key":"pone.0226320.ref005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa035144","article-title":"Once-daily valacyclovir to reduce the risk of transmission of genital herpes","volume":"350","author":"L Corey","year":"2004","journal-title":"N Engl J Med"},{"key":"pone.0226320.ref006","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.coviro.2016.01.021","article-title":"Evolution of rational vaccine designs for genital herpes immunotherapy","volume":"17","author":"JK Kaufmann","year":"2016","journal-title":"Curr Opin Virol"},{"issue":"10","key":"pone.0226320.ref007","doi-asserted-by":"crossref","first-page":"e76407","DOI":"10.1371\/journal.pone.0076407","article-title":"A novel DNA vaccine technology conveying protection against a lethal herpes simplex viral challenge in mice","volume":"8","author":"JL Dutton","year":"2013","journal-title":"PLoS One"},{"key":"pone.0226320.ref008","first-page":"0","article-title":"An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1","author":"JL Dutton","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"pone.0226320.ref009","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/CJI.0000000000000156","article-title":"DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection","volume":"40","author":"J Chandra","year":"2017","journal-title":"J Immunother"},{"issue":"11","key":"pone.0226320.ref010","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/infdis\/jiy372","article-title":"Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals","volume":"218","author":"E Agyemang","year":"2018","journal-title":"J Infect Dis"},{"issue":"12","key":"pone.0226320.ref011","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.1172\/JCI57148","article-title":"HSV-2: in pursuit of a vaccine","volume":"121","author":"C Johnston","year":"2011","journal-title":"J Clin Invest"},{"issue":"12","key":"pone.0226320.ref012","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/infdis\/jiy415","article-title":"Effects of Different Doses of GEN-003, a Therapeutic Vaccine for Genital Herpes Simplex Virus-2, on Viral Shedding and Lesions: Results of a Randomized Placebo-Controlled Trial","volume":"218","author":"N Van Wagoner","year":"2018","journal-title":"J Infect Dis"},{"issue":"3","key":"pone.0226320.ref013","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3390\/vaccines2030537","article-title":"Peptide Dose and\/or Structure in Vaccines as a Determinant of T Cell Responses","volume":"2","author":"GR Leggatt","year":"2014","journal-title":"Vaccines (Basel)"},{"issue":"6","key":"pone.0226320.ref014","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/infdis\/jix004","article-title":"Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized Trial","volume":"215","author":"DI Bernstein","year":"2017","journal-title":"J Infect Dis"},{"issue":"44","key":"pone.0226320.ref015","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1016\/j.vaccine.2016.09.001","article-title":"Immune responses elicited by the GEN-003 candidate HSV-2 therapeutic vaccine in a randomized controlled dose-ranging phase 1\/2a trial","volume":"34","author":"JB Flechtner","year":"2016","journal-title":"Vaccine"},{"issue":"5","key":"pone.0226320.ref016","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/ni.1718","article-title":"Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus","volume":"10","author":"T Gebhardt","year":"2009","journal-title":"Nat Immunol"},{"issue":"7424","key":"pone.0226320.ref017","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature11522","article-title":"A vaccine strategy that protects against genital herpes by establishing local memory T cells","volume":"491","author":"H Shin","year":"2012","journal-title":"Nature"},{"issue":"12","key":"pone.0226320.ref018","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1089\/hum.2014.024","article-title":"Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine","volume":"25","author":"R Rosales","year":"2014","journal-title":"Hum Gene Ther"},{"issue":"2","key":"pone.0226320.ref019","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ygyno.2015.11.026","article-title":"A pilot study of pNGVL4a-CRT\/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2\/3 (CIN2\/3)","volume":"140","author":"RD Alvarez","year":"2016","journal-title":"Gynecol Oncol"},{"key":"pone.0226320.ref020","article-title":"GEN-003 Phase 2 Interim Results: therapeutic Vaccine for Genital Herpes Significantly Reduces Viral Shedding and Genital Lesions","author":"KW Van Wagoner N","year":"2015","journal-title":"ID Week"},{"key":"pone.0226320.ref021","unstructured":"MP M. Therapeutic DNA vaccine for genital herpes. ASM\/ICAAC; Boston, MA2016."},{"issue":"4","key":"pone.0226320.ref022","doi-asserted-by":"crossref","first-page":"e0121518","DOI":"10.1371\/journal.pone.0121518","article-title":"Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs","volume":"10","author":"MC Bernard","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"pone.0226320.ref023","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1586\/erv.13.33","article-title":"Synthetic DNA vaccine strategies against persistent viral infections","volume":"12","author":"DO Villarreal","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"10","key":"pone.0226320.ref024","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1089\/vim.2015.0012","article-title":"Herpes Simplex Virus: The Interplay Between HSV, Host, and HIV-1","volume":"28","author":"DV Desai","year":"2015","journal-title":"Viral Immunol"},{"issue":"95","key":"pone.0226320.ref025","doi-asserted-by":"crossref","first-page":"20140160","DOI":"10.1098\/rsif.2014.0160","article-title":"Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding","volume":"11","author":"JT Schiffer","year":"2014","journal-title":"J R Soc Interface"},{"issue":"6","key":"pone.0226320.ref026","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.vaccine.2008.11.074","article-title":"Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa","volume":"27","author":"EE Freeman","year":"2009","journal-title":"Vaccine"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0226320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T20:39:22Z","timestamp":1613162362000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0226320"}},"subtitle":[],"editor":[{"given":"Patricia Evelyn","family":"Fast","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,12,17]]},"references-count":26,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0226320","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,17]]}}}